(BMY) Bristol-Myers Squibb - Ratings and Ratios
Oncology, Immunotherapy, Hematology, Cardiovascular, Neuroscience
Dividends
| Dividend Yield | 4.77% |
| Yield on Cost 5y | 4.92% |
| Yield CAGR 5y | 1.18% |
| Payout Consistency | 90.1% |
| Payout Ratio | 37.8% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 33.4% |
| Value at Risk 5%th | 51.0% |
| Relative Tail Risk | -7.20% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.26 |
| Alpha | -16.52 |
| CAGR/Max DD | -0.20 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.415 |
| Beta | 0.312 |
| Beta Downside | 0.400 |
| Drawdowns 3y | |
|---|---|
| Max DD | 46.85% |
| Mean DD | 27.27% |
| Median DD | 30.33% |
Description: BMY Bristol-Myers Squibb December 02, 2025
Bristol-Myers Squibb (BMY) is a U.S.-based, globally operating biopharmaceutical company that discovers, develops, licenses, manufactures, markets, distributes, and sells prescription medicines across therapeutic areas such as oncology, hematology, immunology, cardiovascular, neuroscience, and others.
The company’s flagship products include Eliquis (anticoagulant for atrial fibrillation and venous thromboembolism), Opdivo (PD-1 checkpoint inhibitor for multiple cancers), Pomalyst/Imnovid (multiple myeloma), Orencia (rheumatoid and psoriatic arthritis), Sprycel (CML), Yervoy (melanoma), Empliciti and Abecma (relapsed/refractory multiple myeloma), and newer launches such as Breyanzi (large B-cell lymphoma), Krazati (KRASG12C-mutated NSCLC), and Sotyktu (plaque psoriasis).
BMY sells its medicines through a diversified network that includes wholesalers, distributors, retail pharmacies, hospitals, clinics, and government programs, giving it broad market reach in both mature and emerging economies.
Founded in 1887 and headquartered in Princeton, New Jersey, the firm was originally known as Bristol-Myers Company before merging with Squibb in 1989 to form the current entity.
Key recent metrics: FY 2023 revenue reached approximately $45.6 billion, up about 12 % YoY, driven largely by strong oncology sales; R&D expenditure was $9.5 billion (≈21 % of revenue), reflecting a continued focus on pipeline expansion. The sector’s macro-driver-an aging global population combined with rising cancer incidence-supports long-term demand for BMY’s specialty drugs, while the company’s dividend yield of roughly 2.8 % and ongoing share-repurchase program provide additional shareholder return levers.
For a deeper, data-rich assessment of BMY’s valuation and risk profile, you might find the analytics on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (6.04b TTM) > 0 and > 6% of Revenue (6% = 2.88b TTM) |
| FCFTA 0.16 (>2.0%) and ΔFCFTA 1.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 15.60% (prev 11.46%; Δ 4.14pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 16.62b > Net Income 6.04b (YES >=105%, WARN >=100%) |
| Net Debt (35.31b) to EBITDA (14.90b) ratio: 2.37 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.04b) change vs 12m ago 0.34% (target <= -2.0% for YES) |
| Gross Margin 65.83% (prev 55.87%; Δ 9.96pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 50.41% (prev 50.64%; Δ -0.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.11 (EBITDA TTM 14.90b / Interest Expense TTM 1.96b) >= 6 (WARN >= 3) |
Altman Z'' 2.00
| (A) 0.08 = (Total Current Assets 35.63b - Total Current Liabilities 28.14b) / Total Assets 96.89b |
| (B) 0.18 = Retained Earnings (Balance) 17.09b / Total Assets 96.89b |
| (C) 0.10 = EBIT TTM 9.99b / Avg Total Assets 95.28b |
| (D) 0.20 = Book Value of Equity 15.87b / Total Liabilities 78.29b |
| Total Rating: 2.00 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 73.97
| 1. Piotroski 6.0pt |
| 2. FCF Yield 11.39% |
| 3. FCF Margin 31.86% |
| 4. Debt/Equity 2.75 |
| 5. Debt/Ebitda 2.37 |
| 6. ROIC - WACC (= 5.58)% |
| 7. RoE 34.65% |
| 8. Rev. Trend 37.61% |
| 9. EPS Trend -14.29% |
What is the price of BMY shares?
Over the past week, the price has changed by +5.59%, over one month by +13.95%, over three months by +12.80% and over the past year by -6.57%.
Is BMY a buy, sell or hold?
- Strong Buy: 4
- Buy: 4
- Hold: 18
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the BMY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 52.8 | 1.6% |
| Analysts Target Price | 52.8 | 1.6% |
| ValueRay Target Price | 55.9 | 7.7% |
BMY Fundamental Data Overview November 26, 2025
P/E Trailing = 16.082
P/E Forward = 7.8927
P/S = 2.0788
P/B = 5.2408
P/EG = 2.2562
Beta = 0.309
Revenue TTM = 48.03b USD
EBIT TTM = 9.99b USD
EBITDA TTM = 14.90b USD
Long Term Debt = 44.47b USD (from longTermDebt, last quarter)
Short Term Debt = 4.72b USD (from shortTermDebt, last quarter)
Debt = 51.04b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 35.31b USD (from netDebt column, last quarter)
Enterprise Value = 134.39b USD (99.85b + Debt 51.04b - CCE 16.50b)
Interest Coverage Ratio = 5.11 (Ebit TTM 9.99b / Interest Expense TTM 1.96b)
FCF Yield = 11.39% (FCF TTM 15.30b / Enterprise Value 134.39b)
FCF Margin = 31.86% (FCF TTM 15.30b / Revenue TTM 48.03b)
Net Margin = 12.57% (Net Income TTM 6.04b / Revenue TTM 48.03b)
Gross Margin = 65.83% ((Revenue TTM 48.03b - Cost of Revenue TTM 16.41b) / Revenue TTM)
Gross Margin QoQ = 71.89% (prev 65.78%)
Tobins Q-Ratio = 1.39 (Enterprise Value 134.39b / Total Assets 96.89b)
Interest Expense / Debt = 0.94% (Interest Expense 480.0m / Debt 51.04b)
Taxrate = 29.51% (919.0m / 3.11b)
NOPAT = 7.04b (EBIT 9.99b * (1 - 29.51%))
Current Ratio = 1.27 (Total Current Assets 35.63b / Total Current Liabilities 28.14b)
Debt / Equity = 2.75 (Debt 51.04b / totalStockholderEquity, last quarter 18.55b)
Debt / EBITDA = 2.37 (Net Debt 35.31b / EBITDA 14.90b)
Debt / FCF = 2.31 (Net Debt 35.31b / FCF TTM 15.30b)
Total Stockholder Equity = 17.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.23% (Net Income 6.04b / Total Assets 96.89b)
RoE = 34.65% (Net Income TTM 6.04b / Total Stockholder Equity 17.43b)
RoCE = 16.14% (EBIT 9.99b / Capital Employed (Equity 17.43b + L.T.Debt 44.47b))
RoIC = 10.54% (NOPAT 7.04b / Invested Capital 66.81b)
WACC = 4.96% (E(99.85b)/V(150.89b) * Re(7.16%) + D(51.04b)/V(150.89b) * Rd(0.94%) * (1-Tc(0.30)))
Discount Rate = 7.16% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.12%
[DCF Debug] Terminal Value 79.27% ; FCFE base≈14.70b ; Y1≈15.76b ; Y5≈19.21b
Fair Price DCF = 164.8 (DCF Value 335.58b / Shares Outstanding 2.04b; 5y FCF grow 8.04% → 3.0% )
EPS Correlation: -14.29 | EPS CAGR: -3.04% | SUE: -0.28 | # QB: 0
Revenue Correlation: 37.61 | Revenue CAGR: 0.52% | SUE: 1.47 | # QB: 8
EPS next Quarter (2026-03-31): EPS=1.49 | Chg30d=-0.003 | Revisions Net=+2 | Analysts=8
EPS next Year (2026-12-31): EPS=5.99 | Chg30d=-0.056 | Revisions Net=+0 | Growth EPS=-8.5% | Growth Revenue=-8.2%
Additional Sources for BMY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle